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Objective The`HICPACguidelines', published in theUSA in1995 stressed the crucial role of restrictive
usage of glycopeptides in the strategy to limit the emergence and spread of resistant enterococci. Because
controversy still remains in Belgiumon the necessity and feasability of restricting glycopeptide usage, the
infectious diseases advisory board (IDAB) developed a consensus statement on the judicious use of
glycopeptides in Belgium.
Methods The literature on the indications for glycopeptide treatment was reviewed, categorized and
discussed by aworking party of the IDAB.Consequently, the IDAB reached consensus on thewarranted
indications for glycopeptide use in Belgium.
Results The opinion of the IDAB-members is reported in a consensus statement specifying the
indications for treatment and for prophylaxis with glycopeptide antimicrobials, as well as the situations
where glycopeptides should not be used, taking into account the speci¢c epidemiologyof bacterial
resistance, the availability of antibiotics and the commonprescribing practices in Belgium.
Conclusions The IDAB concludes that restrictive usage of glycopeptides must also be a priority in
Belgium. Guidelines on the judicious use of these antibiotics adapted to the national situations must
contribute to this objective.
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I N T R O D U C T I O N
The glycopeptide antibiotics vancomycin and teicoplanin
became the ¢rst choice antibiotics to treat severe Gram-posi-
tive infections in hospitals, especially as a consequence of the
nosocomial pandemic of methicillin-resistant Staphylococcus
aureus (MRSA). The abundant use of glycopeptides in many
hospitals may cause or promote the emergence and spread of
resistant pathogens [1] like vancomycin-resistant enterococci
(VRE) [2,3], vancomycin- or teicoplanin-resistant S. aureus
[4^6] S. epidermidis [7] and S. hemolyticus [8]. In the USA, a
consensus paper referred to as `the HICPAC guidelines', was
published in 1995 [9]. This paper proposes a strategy to limit
the spread of VRE, consisting of infection control measures,
information about the epidemiology of VRE to the hospital
sta¡, and last but not least, a consensus to restrict the use of
glycopeptides to essential indications.
Methicillin-resistant strains of staphylococci are endemic
nosocomial pathogens. Coagulase-negative staphylococci
exhibit b-lactam resistance in 70^80% of the strains from hos-
pitalized patients and co-resistance to aminoglycosides,
macrolides-lincosamides and £uoroquinolones is frequent.
The prevalence of MRSA infections in many Belgian hospi-
tals increased rapidly during the 1980s: the proportion of
MRSA in nosocomial S. aureus bacteremia rose from 10% in
1984 to 31% in1992 [10].The incidence of MRSA nosocomial
acquisition varied widely among acute care hospitals [11].
After implementation of control measures following consen-
sus guidelines published in 1993, the median incidence of
MRSA nosocomial acquisition decreased from 3.6 to1.5 cases/
1000 admissions during the period 1994^99 (National MRSA
SurveillanceReport,1999). As observed in neighboring coun-
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tries, widespread clones of MRSA multiresistant to gentami-
cin, macrolides-lincosamides, rifampin and £uoroquinolones
predominated in the 1980s and have progressively been
replaced during the 1990s by new epidemic MRSA clones
exhibiting less resistance to other classes of antimicrobials
(susceptible to gentamicin, macrolides-lincosamides, and
rifampin) [12]. Over 95% MRSA strains from Belgiumwere
susceptible to fusidic acid, minocycline and cotrimoxazole.
Although VRE do not yet cause large nosocomial epi-
demics in Belgium, it has been well documented that asymp-
tomatic carriers of VRE occur in Belgian hospitals and in the
community as early as 1993 [13].Therefore, the increase in gly-
copeptide use in Belgium [14] is reason for concern. Still, con-
troversy remains on the feasability of restricting glycopeptide
usage. In Belgium, the HICPAC guidelines are not generally
applied and by many considered too strict. Therefore, the
Infectious Diseases Advisory Board (IDAB) re-evaluated the
indications for judicious use of glycopeptides in Belgium.
M A TE R IA L S A N D M E TH O D S
Based on the HICPAC recommendations, the IDAB studied
the literature in order to evaluate for which indications the
advantages of glycopeptide treatment outmeasure the disad-
vantages both for the individual patient and for the population
of Belgian patients, taking into account the national situation
regarding availability of alternative antibiotics and the preva-
lence of bacterial resistance to antimicrobials.
The MEDLINE reference database was examined for arti-
cles referring to the following keywords: vancomycin, teico-
planin, glycopeptide, monitoring, drug levels, nephrology,
posology, peritonitis, CAPD, hemodialysis. The obtained
references were examined, categorized and discussed. Conse-
quently the IDAB reached consensus on the warranted indica-
tions for glycopeptide use in Belgium, specifying indications
for treatment and for prophylaxis, as well as on the situations
where glycopeptides should not be used.
R ES U L T S
Indications for treatment with glycopeptides
Glycopeptides are widely used to treat di¡erent categories of
infections. The working group reached consensus about the
appropriateness of glycopetide treatment for bacteriologically
documented or clinically suspected infections as summarized
below.
Bacteriologically documented infections
Most penicillin-resistant strains of S. pneumoniae in Belgium
exhibit a low level of resistance (minimal inhibitory concen-
tration (MIC) 0.12^1.0mg/L) [15]. Respiratory tract infec-
tions therefore can be treated with high dose penicillin.
Infection with strains with MIC>1.0mg/L can be treated
with a third-generation cephalosporin or a carbapenem. S.
pneumoniae strains with MIC for penicillin>1mg/L causing
infections of the central nervous system should be treatedwith
meropenem [16].
Methicillin-susceptible S. aureus (MSSA) infections should
be treated with penicillinase-resistant penicillins and MRSA
with glycopeptides. MRSAmust be considered to be resistant
to all b-lactams (even associated with a b-lactamase inhibitor)
and also to carbapenems [17].
Combination of a glycopeptidewith rifampin or an amino-
glycoside is advocated for MRSA endocarditis, osteoarthritis
and severe infection of immunocompromised patients,
because of the poor bactericidal activity of glycopeptides [18].
Although no hard data support the clinical relevance of
synergy between b-lactams and aminoglycosides or rifampin,
most authors recommend combination therapy for staphyloc-
cocal endocarditis and other severe deep-seated staphylococcal
infections.
Ampicillin (or ureidopenicillin) remains the treatment of
choice for enteroccocal infection in Belgium (associated with
an aminoglycoside for endocarditis). Glycopeptides are not
indicated unless an ampicillin-resistant enterococcus is con-
sidered to be the cause of infection, provided that all pus and
all catheters or other foreign bodies are removed from the
infection site [19].
Catheters infected by coagulase-negative staphylococci
(CNS) in non-neutropenic patients should be removed and
not treated with antibiotics. Glycopeptides must be reserved
to treat severe CNS infections that also necessitate drainage
and/or removal of all foreign devices.
Glycopeptides are never indicated to treat streptococcal
infections, except when caused by a rare strain of viridans strep-
tococcuswith high level resistance to penicillin.
Severe infections due to C. jeikeium often occur in cancer
patients or in patients with prosthetic devices, particulary car-
diac prosthesis. Although most Corynebacterium spp. are sus-
ceptible to penicillin, C. jeikeium infection requires treatment
withvancomycin [20].
Empirical treatment of severe infections
The necessity must be stressed for relevant and validated epi-
demiological data, collected and published on both national
and local levels. Based on these reports, the clinician must be
able to evaluate the risk that the individual infection is caused
by a pathogen resistant to the standard treatment for the given
clinical situation. For each empirical treatment this risk should
be documented before prescribing glycopeptides.
Infections in the newborn. Glycopeptides are indicated to
treat infections related to indwelling catheters in newborns
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admitted to an intensive care unit, providing that the causative
pathogen is not known.Those infections are frequent, hard to
document clinically and bacteriologically, and often caused by
methicillin-resistant CNS [21,22].
Burned patients. This type of patient usually su¡ers from
skin and soft-tissue infections, catheter-related infections and
pneumonia. Encountered pathogens are S. aureus, Pseudomonas
aeruginosa and (infrequently) Enterococcus faecalis and CNS [23].
Glycopeptides are only indicated if the burned patient is
admitted in a unit where the prevalence of MRSA is known to
be high.
Clinical sepsis. Empirical treatment with glycopeptides can
only be considered when the sepsis is severe, probably cathe-
ter-related andwhen the catheter cannot be removed.
Except in particular epidemiological situations, glycopep-
tides are never indicated to treat intra-abdominal sepsis
empirically, unless b-lactam resistant Enterococcus spp. or
MRSAwere previously isolated from the patient.
Infections in a patient with indwelling percutaneous cathe-
ters. The clinical diagnosis of catheter-related sepsis is rela-
tively easy if local in£ammation or pus is present. Otherwise,
one must rely on the microbiologial (semiquantitative) culture
of blood and/or the removed catheter.The treatment of choice
is to remove the catheter and to associate or not systemic anti-
biotherapy. Glycopeptide treatment is indicated for septic
unstable patients prior to bacteriogical documentation of the
infection andwhen the catheter cannot be removed [24].
Peri-prosthetic or other foreign body infections. They rarely
necessitate empirical antibiotic treatment. For prosthetic valve
endocarditis glycopeptides are part of the classical empirical
treatment. For natural valve endocarditis, however, glycopep-
tides are not empirically needed because b-lactam-resistant
pathogens are exceptional in this setting.
Meningitis. should not be treated with glycopeptides as long
as penicillin-resistance of S. pneumoniae (MIC>1mg/L) is
uncommon.
Meningitis in the presence of a foreign body, an anatomical
abnormality or after a previous surgical procedure is often
caused by S. aureus, enterococci and CNS, but the early di¡er-
ential diagnosis between sterile post-surgical meningitis and
bacterial meningitis is cumbersome. In this setting a glyco-
peptide is indicated when the microscopic examination of the
CSF is either inconclusive or shows Gram-positive cocci or
when the prevalence of MRSA is high in the hospital unit. A
derivative shunt should be removed, or changed and £ushed
with vancomycin (4^10mg) [25].
Infections caused by Gram-positive pathogens in patients
with severe allergy to b-lactam antibiotics
Patients with suspected IgE-mediated allergy to penicillin
need to be assessed by Rast test or cutaneous test.There are no
good reliable tests to con¢rm cephalosporin allergy [26] but
cross-allergy with penicillin is rare. Most often in those cases,
alternative treatments can be proposed. Infections with S.
pneumoniae can most often be treated with cephalosporins; S.
pyogenes with macrolides, S. aureus or Enterococcus spp. with
cotrimoxazole.
In allergic patients, penicillin can sometimes be administred
cautiously or, preferrably, a rapid desensitization can be carried
out. For patients without bacteriological documentation, we
recommend cotrimoxazole, lincosamides or cephalosporins
according to the clinical diagnosis.
Treatment of Gram-positive infections caused by penicillin-
susceptible pathogens with glycopeptides
In particular circumstances, when the administration of glyco-
peptides is more convenient, or when the treatment is of long
duration and could be continued in the ambulatory setting,
teicoplanin intramuscularly could be used instead of another
intravenous drug. But these circumstances must be clearly
limited to some cases like endocarditis or osteitis.
Antibiotic-associated colitis (AAC) caused by Clostridium
di¤cile
For mild to moderate AAC, the only required treatment is
withholding all antibiotics. Treatment with oral metronida-
zole is indicated if the causative agent cannot be stopped, if
fever, leucocytosis or abdominal pain is prominent, when
there is peritoneal reaction or in the elderly [27]. This treat-
ment is equivalent to the use of oral vancomycin [28]. Oral
vancomycin is only indicated for severe AAC [29,30], and
results in improvement in 2 days.
Although metronidazole could be ine¡ective in some ser-
iously ill or neutropenic patients [31,32] due to its rather poor
concentration into the intestinal lumen or to exceptional anti-
microbial resistance, it has been advocated as the ¢rst choice by
the Belgian consensus group [33] for treatment of AAC.
Indications for prophylaxis with glycopeptides
Endocarditis prophylaxis
In 1995 the European Heart Journal [34] published a consensus
article on antibiotic prophylaxis for infective endocarditis.
The only indication for vancomycin in this setting is the high
risk patient who has a proven allergy to penicillin.
Surgical prophylaxis in speci®c situations
The Belgian High Council of Health stated in his recommen-
dations of 1997 that routine use of glycopeptides for prophy-
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laxis is not indicated in a hospital solely because of a high inci-
dence of MRSAorMRSE.The prophylactic use of glycopep-
tides is indicated only for the proven MRSA carrier in whom
decontamination has failed or could not be performed. Also,
at institutions with a high rate of (postoperative) infections
caused by S. aureus during an outbreak of MRSA infections,
glycopeptides can be used in prophylaxis for major surgical
procedures involving implantation of prosthetic material or
devices (cardiac and vascular procedures, total hip replace-
ment, ventricular shunts). No data are published concerning
the threshold of resistance prevalence that should lead to pro-
pylactic use of glycopeptides. More important than the pro-
phylactic use of glycopeptides is to instill appropriate hygiene
measures to stop theMRSAepidemic.
Clinical situations where glycopeptides should not be used
Routine prophylaxis
No data support adequately the use of glycopeptides for the
prophylaxis of infection or catheter-related sepsis. The best
prophylaxis is to use adequate aseptic techniques. Glycopep-
tides should not be used prophylactically in the neonatal inten-
sive care unit[35^37]. Some limited randomized studies have
indeed shown a reduction of CNS septicemia but no reduc-
tion in the length of the stayor mortality.
The prophylactic use of glycopeptides is unanimously
rejected either for hemodialysis (HD) or continuous ambula-
tory peritoneal dialysis (CAPD) as described in the 1996 ver-
sion of the A`dvisory Committee on Peritoneal Management
of the International Society for Peritoneal Dialysis' [38] (ACP-
MISPD).
The empirical use of glycopeptides in neutropenic fever
Early studies [39] have advocated that glycopeptides should
be administered promptly to treat neutropenic fever, because
of the low incidence of treatment failure [40] and the occur-
rence of lethal Gram-positive superinfections during mono-
therapy with ceftazidime [41]. However, a retrospective
analysis of this `front-loading' approach demonstrated that in
at least 80% of the cases, glycopeptides were given unnecessa-
rily [42]. Numerous large-scale clinical trials have now con-
¢rmed that omitting glycopeptides from the early treatment
does not adversely a¡ect infectious morbidity and mortality,
duration of fever, microbiological e¤cacy or number of infec-
tions, even when in£ammation of soft-tissue or catheter exit
site is present [43^46]. Since the median time to defervescence
in patients receiving adequate antibiotic coverage is 4^5 days,
supplementing glycopeptides should not be considered before
96 h of unexplained fever in a clinically stable patient [45]
including the bonemarrow transplant recipient [46].
When fever persists, no microbial pathogens are identi¢ed
and no other clinical signs of infection are present, glycopep-
tides are often added to the initial antimicrobial treatment
[46], although it has been demonstrated that this approach
o¡ers no bene¢t [47]. Moreover, the German International
Antimicrobial Strategy Study has clearly demonstrated the
superiority of supplementing broad-spectrum antifungals
over additional (glycopeptide) antibiotics [48].Therefore, gly-
copeptides should only be given for FUO in addition to the
empirical treatment when the patient's condition is unstable.
Isolation of coagulase-negative staphylococci from a single
blood culture
As a rule, one can state that an isolated positive blood culture
does not warrant the use of vancomycin or teicoplanin when
further blood cultures taken during the same time frame
remain negative [49].
Selective digestive decontamination (SDD) and eradication
of MRSA colonization
The use of vancomycin has been advocated as part of SDD in
hematological or intensive care wards [50].The bene¢t of such
an attitude is doubtful compared with the risk of selection of
resistant strains of enterococci [51] and of bacteremia due to
coagulase-negative staphylococci [52].
The use of vancomycin, either systemic or topical, is usually
ine¡ective for decontamination of the patient colonized by
MRSA. A better approach is to use intranasal mupirocin and
aseptic baths.
Treatment with glycopeptides of infections caused by b-
lactam-susceptible Gram-positive microorganisms in
patients with renal failure
A single dose of vancomycin every 7 days generally provides
a su¤ciently high serum level of antibiotic to protect the
patient with terminal renal failure against Gram-positive
infections.The patient can be treated ambulatory [53], interac-
tion with orally administrated drugs is avoided and the com-
pliance is good. So it is understandable that some
nephrologists have reacted vigorously against the HICPAC
guidelines and still prescribe glycopeptides to treat infections
caused by b-lactam-susceptible pathogens.
The A`CPMISPD'and others [54] recommends cefazolin or
cephalothin intraperitoneal aminoglycoside [38,55] for the
empirical treatment of peritonitis in CAPD. Vancomycin is
only indicated for infection due toMRSAorMRSE.
In Europe, most enterococcal strains remain sensitive to
ampicillin. In Belgium a recent surveillance study demon-
strated that 14.3^66% of patients on chronic hemodialysis are
colonized with GRE [56]. Nevertheless, some nephrologic
units prescribe vancomycin in empirical treatment of infec-
tionswhen the prevalence of MRSA is high.
In the IDAB's opinion, an hemodialysis unit where MRSA
infections are frequent (>10% of all infections caused by
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MRSA) must make every attempt to contain the epidemic in
order to enable the ¢rst-line use of ¢rst-generation cephalos-
porins instead of glycopeptides. In these wards, the control of
patient/sta¡ MRSA nasal carriage is mandatory. The carriers
should be treated with mupirocin and cohorted if the treat-
ment is ine¡ective.
Dosing and monitoring of glycopeptides drug levels
Correct dosing of glycopeptides is critical (Table1) [57]. Posol-
ogy for di¡erent situations was analyzed from the literature
[58^77] and summarized inTable 2.
Systematic monitoring of blood levels during vancomycin
treatment was traditionnally recommended [78], but more
recently, the usefulness of this practice was repeatedly ques-
tionned [59, 79, 80]. It can be concluded that monitoring of
vancomycin is useful in the following situations: combination
treatment with an aminoglycoside, treatment with a higher
dose than usual, when the patient is dialyzed with `high £ux'
membranes, in patients with major burns, in intravenous drug
addicts or when renal function is rapidly changing [57,78,80].
Serum levels should be determined twice a week and levels of
5^10mg/L and 2 h peak concentration of 20^40mg/L are
aimed for.
For teicoplanin, contrary to vancomycin, monitoring is
not recommended by the manufacturer [73]. However, serum
levels should be monitored during treatment of S. aureus
endocarditis or septic arthritis, where a trough concentration
of at least 20mg/L instead of 10mg/L is needed. It may also be
indicated to determine teicoplanin concentrations in patients
with major burns, in intravenous drug addicts or when renal
function is rapidly changing.
It is useful to mention that teicoplanin needs a loading
dose at the ¢rst dayof administration.
C O N C L U SI O N
The emergence of resistant Gram-positive microorganisms
renders the restriction of glycopeptide usage urgent. Several
strategies towards judicious use of these antimicrobial agents
Table 1 Recommended dosage of vancomycin and teicoplanin in different clinical situations
Clinical situation Vancomycin Teicoplanin
1 General rules
Loading dose 15 mg/kg 6 or 12a mg/kg 3 times
Next doses 15 mg/kg 6 or 12a mg/kg
Interval between doses
GFR>90 12 h 24 h
GFR50±90 12±24 h 24 h
GFR10±50 24±96 h 48 h
GFR<10 96±168 h 72 h
2 Hemodialysis 15 mg/kg/weekb 12 mg/kg as loading dose
then 6 mg/kg at day 2 and day 3c
then 6 mg/kg/week
3 CAPD peritonitis IV: 15 mg/kg/week IV: cf posology GFR< 10
IP: 30 mg/kg/week IP: 1st week 20 mg/L in each bag
2nd week 20 mg/kg every other bag
3rd week 20 mg/kg in the night bag
4 CAVH(D)-CVVH(D) cf GFR 10±50 mL/min cf GFR 10±50 mL/min
5 Neonatology
Age, weight
0±7 days, >1200 g 30 mg/kg/12 h Not indicated
0±7 days, <1200 g 15 mg/kg/12 h Not indicated
8ÿ 28 days, >1200 g 45 mg/kg/08 h Not indicated
8±28 days, <1200 g 15 mg/kg/24 h Not indicated
6 Pediatrics
Interval between doses 40 mg/kg/24 h 3 loading doses at 10 mg/kg every 12 h then 6±10 mg/kg/24 h
aIn case of S. aureus endocarditis or septic arthritis; bmonitoring needed mainly if high ¯ux membranes are used; cD2, D3, D5, D12, D17 in
case of S. aureus endocarditis; IV: intravenous; IP: intraperitoneal.
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have been proposed internationally, but are not generally
implemented in Belgium. The IDAB proposes these guide-
lines to the Belgian prescribers based on literature review and
consensus panel discussions. The detailed document has been
propagated among hospital physicians and pharmacists, and
can be used to set up local projects on evaluation of glycopep-
tide utilization.
A C K N O W LE D G M EN T S
The Infectious Diseases Advisory Board comprises: A. Bosly,
Yvoir; M. Delme¨e, Bruxelles; E. Firre, Lie© ge; PF. Laterre,
Bruxelles; JC. Legrand, Charleroi;Y. Sibille,Yvoir; M. Strue-
lens, Bruxelles;Y.Van Laethem, Bruxelles; F. Colardyn, Gent;
H. Goossens, Edegem; B. Gordts, Brugge; P. Jordens, Aalst; J.
Maertens, Leuven; W. Peetermans, Leuven; Y. Valcke, Sint
Niklaas; J.Van Eldere, Leuven;W.Vincken, Brussel; D. Voge-
laers, Gent.
Our special thanks go to Ms. E.Van Brackel (GlaxoWell-
come, Brussels, Belgium) for professional logistic support.
R E F ER E N C ES
1. Courcol RJ, Pinkas GR,Martin GR. A seven-year surveyof anti-
biotic susceptibility and its relationship with usage. J Antimicrob
Chemother1989; 23: 441^51.
2. Leclercq R, Derlot E, Duval J, Courvalin P 1988 Plasmid
mediated resistance to vancomycin and teicoplanin in Enterococcus
faecium.NEnglJMed; 319: 157^61.
3. Nosocomial enterococci resistant to vancomycin United States
1989^1993.MMWRMorbMortalWklyRep1993; 42: 597^9.
4. Van Eldere J, Hoefnagels-Schuermans A, Peetermans WE, Van
Lierde S,Verwaest C. Nosocomial transmission of a methicillin-
resistant Staphylococcus aureus strain with reduced teicoplanin sus-
ceptibility. Abstracts of the 37th Interscience Conference on Antimicrob
Agents and Chemotherapy. American Society for Microbiology:
WashingtonDC. Abstract J 122.
5. Kaatz GW, Seo SM,Dorman NJ, Lerner SA. Emergence of teico-
planin resistance during therapyof Staphylococcus aureus endocardi-
tis. J InfectDis1990;162: 103^8.
6. Denis O, Nonho¡ C, Byl B, Knoop C, Struelens MJ. Emergence
of vancomycin intermediate Staphylococcus aureus (VISA) in
patients with methicillin resistance S. aureus (MRSA) infection in
a Belgian hospital. Abstracts of the 10th European Congress of Clinical
Microbiologyand InfectiousDiseases 2000. 2000: Abstract 938.
Table 2 Clinical situations where glycopeptides are indicated
Clinical situation Glycopeptide indicated:
Pathogen identi®ed as:
S. pneumoniae IgE-mediated allergy to penicillin
S. aureus Serious infection caused by methicillin-resistant strain
Enterococcus spp. Serious infection caused by ampicillin-resistant strain
Coagulase-neg. Staphylococcus spp. Serious infection caused by methicillin-resistant strain
Empirical treatment
Newborn in intensive care unit Suspected sepsis caused by coagulase-negative Staphylococcus spp.
and high prevalence of methicillin-resistance, or intubated patient,
or presence of intravascular line
Burned patient Only when prevalence of methicillin-resistance is high among S. aureus
Sepsis Only when related to catheter that cannot be removed and while
awaiting microbiology reports
Serious intra-abdominal infection Only when patient recently carried ampicillin-resistant Enterococcus spp.
or methicillin-resistant S. aureus
Infection of orthopedic or vacular implant Only when prevalence of methicillin-resistance is high among S. aureus
Endocarditis Infected arti®cial heart valve
Meningitis When related to implant, malformation, or recent neurosurgical
procedure and Gram-positive cocci present in microscopic examination
of cerebrospinal ¯uid
b-lactam allergy IgE-mediated allergy to penicillin AND proven
Gram-positive infection
Antibiotic-associated colitis Life-threathening infection
Prophylaxis
Endocarditis When prophylaxis with antimicrobials is indicated and risk category is high
AND IgE-mediated allergy to penicillin
Surgery Cardiovascular surgery and IgE-mediated
allergy to penicillin
Ventricular shunt Administered by installation
äñò Clinical Microbiology and Infection, Volume 6 Number 11, November 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 585±592
7. O'Connell B, Browne PV, Ce¡erkey MT, McCann SR. Coagu-
lase negative Staphylococcal bacteremia treatedwith teicoplanin. J
AntimicrobChemother1993; 31: 438^9.
8. Biavasco F, Giovanetti E, Montanari MP et al. Development of
resistance to glycopeptide antibiotics: assessment in staphylococci
of di¡erent species. JAntimicrobChemother1991; 27: 71^9.
9. Recommendations for preventing the spread of vancomycin resis-
tance. Hospital Infection Control Practices Advisory Committee
(HICPAC) InfectControlHosp Epidemiol1995;16: 105^13.
10. Struelens MJ. Canwe control the rise of methicillin-resistant Sta-
phylococcus aureus?ActaClinicaBelgica1994; 49: 63^7.
11. Struelens MJ, Ronveaux O, Jans B, Mertens R, the GDEPIH-
GOS-PIZ. Methicillin-resistant Staphylococcus aureus epidemiol-
ogy and control in Belgian hospitals: 1991^95. Infect Control Hosp
Epidemiol1996;17: 503^8.
12. Deplano A,Witte W,Van LeeuwenWJ, Brun and Struelens MJ.
Clonal dissemination of epidemic methicillin-resistant Staphylo-
coccus aureus in Belgium and neighbouring countries.ClinMicrobiol
Infect 2000; 5: 239^45.
13. Gordts B,Van Landuyt H, Ieven M,Vandamme P, Gooossens H.
Vancomycin-resistant enterococci colonising the intestinal tract of
hospitalized patients. JClinMicrobiol1995; 33: 2842^6.
14. Gordts B,Van Landuyt H, Hindryckx M. Het antibioticumvoors-
chrift binnen het ziekenhuis.Tijdschrift Voor Geneeskunde 1997; 53
(1): 40^5.
15. Verhaegen J,Van deVenN,Verbiest J,Van Eldere J,Verbist L. Evolu-
tion of Streptococcus pneumoniae serotypes and antibiotic resistance
in Belgiumÿupdate 1994^98. Clin Microbiol Infect 2000; 6: 308^
15.
16. Bradley JS, Scheld WR. The challenge of penicillin-resistant
Streptococcus pneumoniae meningitis: current antibiotic therapy in
the1990s.Clin InfectDis1997; 24S2: 213^231.
17. Lowny FD. Staphylococcus aureus infections. N Engl J Med 1998;
338: 520^32.
18. WilsonWR, Karchnen AW, Dajani AC et al. Antibiotic treatment
of adults with infective endocartitis due to streptococci, enteroc-
cocci, staphylococci and HACEKmicroorganisms. Jama1995; 274:
1706^13.
19. Nichols RL, Muzik AC. Enterococcal infection in surgical
patients: themystery continues.Clin InfectDis1992;15: 72^6.
20. Brown AE. Other Corynebacteriua and Rhodocuccus. In: Man-
dell GL, Bennett JE,DolinR, eds. Principles and Practice of Infectious
Diseases. NewYork: Churchill Livingstone,1995: 1872^9.
21. Schmidt BK, Kirpalini H, Corey M et al. Coagulase negative sta-
phylococci as true pathogens in new born infants: a cohort study.
Pediatri InfectDisJ1987; 6: 1026^31.
22. Schito GC, Pesce A, Debbia EA. Epidemiology of gram positive
pathogens in peditrics patients and implications for therapy.Pediatr
InfectDisJ1993;12: 54^6.
23. Signorini M, Grappolini S, Madciano E, Donati L. Updated eva-
luation of the ativity of antibiotics in a burn center. Burns1992; 18:
500^3.
24. Threlkeld MG, Cobbs CG. Infectious disorders of prosthetic
valves and intravascular devices. In: Mandell GL, Bennett JE,
Dolin R, eds. Principles and Practice of Infectious Diseases. NewYork:
Churchill Livingstone,1995: 783^92.
25. Boaz JC. Cerebrospinal £uid shunt infections. In: Roos KL, ed.
Central Nervous System Infectious Diseases and Therapy. New York:
Marcel Dekker Inc., 1997: 519^44.
26. Anne S, Reisman R. Risk of administering cephalosporin anti-
biotics to patients with histories of penicillin allergy. Ann Allergy
Asthma Immunol1995; 74 (2): 167^70.
27. Fekety R, Shah AB. Diagnosis and treatment of C. di¤cile colitis.
JAMA1993; 269: 71^5.
28. Johnson S, Homann SR, Bettin KM et al.Treatment of asympto-
matic C. di¤cile carriers with vancomycin or metronidazole. Ann
InternMed1992;117: 297^302.
29. Silva JDH, Batts DH, Fekety R. Treatment of C. di¤cile colitis
and diarrheawuithvancomycin.AmJMed1981; 71: 815^22.
30. Fekety R, Silva J, Kaufmann C.Treatment of C. di¤cile antibiotic
associatedwith oral vancomycin.AmJMed1981; 86: 15^9.
31. Rampling A,Warren RE, Berry PJ et al.Atypical C. di¤cile colitis
in neutropenic patients. Lancet1982; 2: 162^3.
32. TeaslyDG, Gerding DN,OlsonMN et al. Prospective randomized
trial of metronidazole vs vancomycin for the treatment of Clostri-
dium di¤cile associated diarrhea and colitis. Lancet1983; 2: 1043^6.
33. Delme¨e M, Melin P, Peetermans W, Verbist L, Verschraegen G.
Treatment of Clostridium di¤cile colitis. Summary of a round table
held in Brussels on March 3rd. Acta Clin Belg 1995 1994; 50 (2):
114^6.
34. Leport C, Horstkotte D, Burckhardt D. Antibiotic profylaxis for
infective endocarditis from an international group of experts
towards a European consensus. Group of Experts of the Interna-
tional Society for Chemotherapy. Eur Heart J 1995; 16 (Suppl. B):
126^31.
35. Moller JC, Nachtrodt G, Tegtmeyer FK et al. Prophylactic low
dose vancomycin treatment in very low birth weight infants. Dev
PharmacolTher1992;19: 178^82.
36. Spa¡ord PS, SinkinRA, Cox C et al. Prevention of central venous
katheter related coagulase negative staphylococcal sepsis in neo-
nates. J Pediatr1994;125: 259^63.
37. Kacica MA, Horgan MJ, Ochoa L. Prevention of Gram-positive
sepsis in neonates weighing less than 1500 grams. J Pediatr 1994;
125: 253^8.
38. Keane WF, Alexander SR, Bailie GR et al. Peritoneal dialysis
related peritonitis treatment recommendations. 1996 update (see
comments). PeritDial Int1996;16: 557^73.
39. Kramer BS, Ramphal R, Rand KH. Randomized comparison
between two ceftazidime-containing regimens and cephalothin-
gentamycin-carbenicillin in febrile granulocytopenic cancer
patients.AntimicrobAgentsChemother1986; 30: 64^8.
40. Karp JE,Dick JD, Angelopulos C et al.Empiric use of vancomycin
during prolonged treatment-induced granulocytopenia: rando-
mised, double-blind, placebo-controlled clinical trial in patients
with acute leukemia.AmJMed1986; 81: 237^42.
41. Ramphal R, Kramer BS, Rand KH, Weiner RS, Shands JW.
Early results of a comparative trial of ceftazidime versus cepha-
lothin, carbenicillin, and gentamycin in the treatment of febrile
granulocytopenic patients. JAntimicrob Chemother 1983; 12 (Suppl.
A): 81^8.
42. Rubin M, Hathorn JW, Marshall J et al. Gram-positive infections
and the use of vancomycin in 550 episodes of fever and neutrope-
nia.Ann InternMed1988;108: 30^5.
43. EORTC. and National Cancer Institute of Canada.Vancomycin
added to empirical combination antibiotic therapy for fever in
granulocytopenic patients. J InfectDis1991;163: 951^8.
44. Nova© kova© IRO,Donnelly JP,De PauwBE. Ceftazidime as mono-
therapy or combined with teicoplanin for initial empiric treat-
ment of presumed bacteremia in febrile granulocytopenic
patients.AntimicrobAgentsChemother1991; 35: 672^8.
45. Ramphal R, Bolger M, Oblon DJ et al. Vancomycin is not an
essential component of the initial empiric treatment regimen for
febrile neutropenic patients receiving ceftazidime: a randomized
prospective study.AntimicrobAgentsChemother1992; 36: 1062^7.
äñ"Gordts et al Guidelines for glycopeptides in Belgium
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 585±592
46. Dompeling EC,Donnelly JP, Deresinski SC et al.Early identi¢ca-
tion of neutropenic patients at risk of Gram-positive bacteraemia
and the impact of empirical administration of vancomycin. Eur J
Cancer1996; 34A: 1332^9.
47. Erjavec Z, deVries-Hospers HG,Van Kamp H et al.A prospective,
randomised, double-blind, placebo-controlled trial of teicopla-
nin in neutropenic patients with persistent fever after imipenem
monotherapy.The tenth International Symposium on Infections in the
ImmunocompromisedHost.Davos, June1998: (abstract 013).
48. Link H, Maschmeyer G, Meyer P et al. Interventional antimicro-
bial therapy in febrile neutropenic patients.AnnHematol 1994; 69:
231^43.
49. Bates DW, Goldman L, LeeTH. Contaminant blood cultures and
resource utilisation.The true consequences of false positive results.
JAMA1991; 265: 365^9.
50. Sanchez M, Mir N, Canton R, Luque R, Lopez B, Baquero F.
The e¡ect of topical vancomycin on acquisition, carriage, and
infection with methicillin-resistant Staphylococcus aureus in criti-
cally ill patients. In: Abstracts of the 37th Interscience Conference on
Antimicrobial Agents and Chemotherapy. American Society for
Microbiology:WashingtonDC,1997: Abstract J 119.
51. Van der Auwera P, Pensart N, KortenV, Murray BE, Leclercq R.
In£uence of oral glycopeptides on the fecal £ora of human volun-
teers: selection of highlyglycopeptide resistant enterococci. J Infect
Dis1996;173: 1129^36.
52. Wade JC, Schimp¡ SC, Newman KA et al. Staphylococcus epider-
midis: an increasing cause of infection in patients with granulocy-
topenia.Ann InternMed1982; 97: 503^8.
53. Golper TA,Tranaeus A.Vancomycin revisited. Perit Dial Int 1996;
16: 116^7.
54. Kuypers D,Vanwalleghem J, Maes B et al. Cefazolin serum con-
centrations with ¢xed intravenous dosing in patients on chronic
hemodialysis treatment.NephrolDialTransplant1999;14: 2050^1.
55. KeaneWF, Everett ED, Golper TA et al. Peritoneal dialysis related
peritonitis treatment recommendations 1993 update.The Ad Hoc
Advisory Committee on Peritonitis Management. International
Society for Peritoneal Dialysis. PeritDial Int1993;13: 14^28.
56. Descheemaeker P, IevenM, Chapelle S et al. Prevalence and mole-
cular epidemiology of glycopeptide resistant enterococci in Bel-
gian renal dialysis units. J InfectDis1999;181: 235^41.
57. LeaderWG, Chandler Castigliam MH. Pharmacokinetic optimi-
sation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327^
42.
58. Sanford JP, Gilbert DN,Moellering RC, SandeMA, eds.TheSan-
ford Guide to Antimicrobial Therapy. Antimicrobial Therapy Inc.,
Hyde Park,Vermont,1997.
59. Cantu TG,YamanakaYuen NA, Lietman PS. Serum vancomycin
concentrations: reappraisal of their clinical value. Clin Infect Dis
1994;18: 533^43.
60. Quale JMO, Halloran JJ, Devincenzo N et al. Removal of vanco-
mycin by high £ux hemodialysis membranes. Antimicrob Agents
Chemother1992; 36: 1424^6.
61. Bohler J, Reetze Bonorden P, Keller E et al. Rebound of plasma
vancomycin levels after haemodialysis with highly permeable
membranes. EurJClin Pharmacol1992; 42: 635^9.
62. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clear-
ance of vancomycin during hemodialysis using polysulfone dialy-
zers.Kidney Int1989; 35: 1409^12.
63. Matzke GRO, Connell MB, Collins AJ et al.Disposition of vanco-
mycin during hemo¢ltration. Clin PharmacolTher 1986; 40: 425^
30.
64. Neville LD, Baillard Brum¢tt RA, Hamilton J. E¤cacy and
safety of teicoplanin in Gram positive peritonitis in patients on
peritoneal dialysis. J Antimicrobial Chemotherapy 1988; 21 (Suppl.
A): 123^31.
65. Davies SP, Azadian Kox BS, BrownWJ,Ti EA. Pharmacokinetics
of cipro£oxacin and vancomycin in patients with acute renal fail-
ure treated by continuous haemodialysis. Nephrol Dial Transplant
1992; 7: 848^54.
66. Moellering RC Jr, Krogstad DJ, Greenblatt DJ.Vancomycin ther-
apy in patients with impaired renal function: a nomogram for
dosage.Ann InternMed1981; 94: 343^6.
67. Matzke GR, Mcgory RW, Halstenson CE, KeaneWF. Pharmaco-
kinetics of vancomycin in patients with various degrees of renal
function.AntimicrobAgentsChemother1984; 25: 433^7.
68. Lake KD, Peterson CDA. simpli¢ed dosing method for initiating
vancomycin therapy. Pharmacotherapy1985; 5: 340^4.
69. Gross JR, Kaplan SL, Kramer WG, Mason EO Jr. Vancomycin
pharmacokinetics in premature infants. Pediatr Pharmacol (New
York) 1985; 5: 17^22.
70. James JK, Palmer SM, Levine DP, RybakMJ. Comparison of con-
ventional dosing versus continuous infusion vancomycin therapy
for patients with suspected or documented gram positive infec-
tions.AntimicrobAgentsChemother1996; 40: 696^700.
71. Wilson AP, Gruneberg RN, Neu H. Dosage recommendations
for teicoplanin. JAntimicrobChemother1993; 32: 792^6.
72. Spencer CM, Bryson HM. Teicoplanin: a pharmacoeconomic
evaluation of its use in the treatment of Gram positive infecties.
Pharmacoeconomics1995; 7 (4): 355^74.
73. Brogden RN, PetersTeicoplanin DH. A reappraisal of its antimi-
crobial activity, pharmacokinetic properties and therapeutic e¤-
cacyDrugs1994; 47: 823^54.
74. GraningerW,Wenisch C,Wiesinger E et al. Experience with out-
patient intravenous teicoplanin therapy for chronic osteomyelitis.
EurJClinMicrobiol InfectDis1995;14: 643^7.
75. ChowAW, Azar RM. Glycopeptides and nephrotoxicity. Intensive
CareMedicine1994; 20: S23^9.
76. Ho¥er D, Koeppe P, Naumann E et al. Pharmacokinetics of teico-
planin in hemodialysis patients. Infection1991;19: 324^7.
77. Beckers B, Brodersen HP, Stolpmannr M et al. E¤cacy and phar-
macokinetics of teicoplanin in hemodialysis patients. Infection
1993; 21: 71^4.
78. Prika RD.Vancomycin serum concentration monitoring: a conti-
nuate debate.TheAnnPharmacotherapy1994; 28: 1397^9.
79. Catchpole C, Hasting JGM. Measuring pre and post dose vanco-
mycin level time for a change?MedMicrobiol1995; 45: 309^11.
80. Moellering RC Jr, Editorial. Monitoring serum vancomycin
levels: climbing the mountain because it is there? Clin infect Dis
1994;18: 544^6.
äñá Clinical Microbiology and Infection, Volume 6 Number 11, November 2000
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 585±592
